On Tuesday, Acurx Pharmaceuticals Inc (NASDAQ: ACXP) opened higher 3.63% from the last session, before settling in for the closing price of $0.47. Price fluctuations for ACXP have ranged from $0.30 to $3.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -7.84%. Company’s average yearly earnings per share was noted 42.53% at the time writing. With a float of $20.39 million, this company’s outstanding shares have now reached $22.40 million.
Let’s determine the extent of company efficiency that accounts for 4 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acurx Pharmaceuticals Inc (ACXP) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Acurx Pharmaceuticals Inc is 13.17%, while institutional ownership is 14.90%. The most recent insider transaction that took place on Jan 06 ’25, was worth 25,000. In this transaction Director of this company bought 24,631 shares at a rate of $1.01, taking the stock ownership to the 27,708 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Director bought 24,631 for $1.01, making the entire transaction worth $25,000. This insider now owns 137,183 shares in total.
Acurx Pharmaceuticals Inc (ACXP) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.59% during the next five years compared to -7.84% drop over the previous five years of trading.
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Trading Performance Indicators
Check out the current performance indicators for Acurx Pharmaceuticals Inc (ACXP). In the past quarter, the stock posted a quick ratio of 1.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Acurx Pharmaceuticals Inc (ACXP)
Looking closely at Acurx Pharmaceuticals Inc (NASDAQ: ACXP), its last 5-days average volume was 0.68 million, which is a drop from its year-to-date volume of 3.19 million. As of the previous 9 days, the stock’s Stochastic %D was 25.23%.
During the past 100 days, Acurx Pharmaceuticals Inc’s (ACXP) raw stochastic average was set at 25.13%, which indicates a significant increase from 9.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1044 in the past 14 days, which was higher than the 0.0423 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4259, while its 200-day Moving Average is $0.9077. However, in the short run, Acurx Pharmaceuticals Inc’s stock first resistance to watch stands at $0.5113. Second resistance stands at $0.5342. The third major resistance level sits at $0.5593. If the price goes on to break the first support level at $0.4633, it is likely to go to the next support level at $0.4382. Should the price break the second support level, the third support level stands at $0.4153.
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Key Stats
There are currently 23,482K shares outstanding in the company with a market cap of 11.47 million. Presently, the company’s annual sales total 0 K according to its annual income of -14,100 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -2,150 K.
